Senores Pharmaceuticals zooms on entering into SPA to acquire 2.97% stake in Havix
Senores Pharmaceuticals is currently trading at Rs. 607.00, up by 18.25 points or 3.10% from its previous closing of Rs. 588.75 on the BSE.
The scrip opened at Rs. 588.75 and has touched a high and low of Rs. 624.30 and Rs. 586.35 respectively. So far 60950 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 664.00 on 19-Mar-2025 and a 52 week low of Rs. 440.00 on 13-Jan-2025.
Last one week high and low of the scrip stood at Rs. 609.45 and Rs. 558.75 respectively. The current market cap of the company is Rs. 2786.93 crore.
The promoters holding in the company stood at 45.77%, while Institutions and Non-Institutions held 13.82% and 40.40% respectively.
Senores Pharmaceuticals has entered into the Share Purchase Agreement (SPA) with one of the shareholders (Public Category) of Havix Group Inc. D/B/A Aavis Pharmaceuticals (Havix) for acquisition of 6730 equity shares of Havix i.e. 2.97% of the total paid up share capital of Havix and subject to the terms and conditions as mentioned in the SPA.
Further, post the aforesaid acquisition the aggregate shareholding of the company (along with the shareholding of its wholly owned subsidiary - Senores Pharmaceuticals Inc.) in Havix will increase from 70.07% to 73.04%.
The Management Committee of Board of Directors of the company, in their meeting held July 10, 2025, has approved the same.
Havix is a US based company engaged in the business of developing, manufacturing and supplying of various finished formulations.
Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms.
.jpg)
